Tauopathies
📧 Sign up to get email alerts when something new happens for Tauopathies.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-06-29Clinical Trial Results: A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation [Phase 2]
Phase 2 trial results for XPro1595 in early Alzheimer's disease with inflammatory biomarkers have been completed and results posted.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503 [EARLY_Phase 1]
This early Phase 1 trial update describes a study of the radiotracer 11C-M503 to assess its biodistribution, metabolism, excretion, and brai…
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: CW2IP2: Imaging and Diagnostic Assessments [NA]
A clinical trial update indicating that CW2IP2 imaging and diagnostic assessments for tauopathies is currently recruiting at the University …
-
CLINICAL_TRIALS trial_result · 2025-12-31Clinical Trial Update: Validation of Blood Biomarkers for Alzheimer's Disease [NA]
A completed clinical trial from University Hospital, Montpellier validating blood biomarkers for Alzheimer's disease and related cognitive d…
-
CLINICAL_TRIALS research · 2025-12-29Clinical Trial Update: [18F]NIDF PET Imaging in Tau-related Diseases
This clinical trial update reports recruitment for a study using the PET imaging tracer [18F]NIDF to visualize tau-related neurodegenerative…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-12-23Clinical Trial Update: Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A [EARLY_Phase 1]
An early-phase (Phase 1) study evaluating biodistribution, metabolism, excretion, and brain uptake of the radiotracer 18F-JSS20-183A. The st…
-
CLINICAL_TRIALS trial_result · 2025-11-19Clinical Trial Update: Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15 [EARLY_Phase 1]
This EARLY Phase 1 study at the University of Pennsylvania is evaluating the biodistribution, metabolism, excretion, and brain uptake of the…
-
FDA approval · 2024-02-05FDA Approved: TAUVID — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for Tauvid (flortaucipir F-18) enabling its use for PET imaging of tau neurofibrillary tangles in ad…
-
CLINICAL_TRIALS research · 2019-12-06Clinical Trial Update: Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations [Phase 2]
Phase 2 study evaluating tau PET imaging with 18F-AV-1451 in individuals with MAPT mutations completed; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2017-11-06Clinical Trial Update: A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects [Phase 1]
Phase 1 randomized, double-blind, placebo-controlled, single ascending dose study of intravenously administered BMS-986168 in healthy subjec…
-
CLINICAL_TRIALS research · 2016-12-16Clinical Trial Update: Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects [Phase 1]
Phase 1 study evaluating the PET tracer [18F]MNI-777 as a marker of tau pathology in tauopathy subjects and healthy controls has been comple…
-
CLINICAL_TRIALS research · 2016-08-09Clinical Trial Update: COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE
This is a completed clinical trial update evaluating the comparative effectiveness of treatments for mild cognitive impairment and dementia …
-
CLINICAL_TRIALS trial_result · 2012-10-01Clinical Trial Update: The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD
This clinical trial update reports the long-term safety and efficacy follow-up of subjects who completed the Phase I study of Neurostem-AD.